Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.
Researchers find blocking the KCNB2 gene can slow tumor growth, paving the way for next-gen treatments for childhood brain cancer.
Genprex has dosed the first subject in the Phase II expansion portion of its Acclaim-3 trial of the Reqorsa gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback